Lausanne Clinical Research Site

The Vaccine and Immunotherapy Center (VIC)

Prof. Giuseppe Pantaleo, MD

From 2007 until 2014, the Lausanne site served as a Clinical Trial Unit (CTU) of the HIV Vaccine Trial Network (HVTN) and beginning in 2014, it serves as a Clinical Research Site (CRS) affiliated with the Seattle CTU. The Lausanne site operates within the Vaccine and Immunotherapy Center (VIC) that was created in 2001 by Prof. Giuseppe Pantaleo, MD, head of the Service of Immunology and Allergy at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. 

Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland

The CHUV is a teaching hospital that provides specialized medical care to half of the Western Swiss area (1,500,000 inhabitants; the other half being covered by the Geneva University Hospital). More than 45,000 patients were hospitalized at the CHUV in 2013 and over 38,000 received care at the emergency care unit. More than 9700 collaborators represent 114 different nationalities. The CHUV enthusiastically supports VIC activities and provides infrastructure, basic equipment and access to diagnostic certified clinical laboratories and a pharmacy.


The VIC is a clinical and laboratory research platform specialized in vaccinology, clinical research, immune-monitoring and basic immunology. Over the years, we have gained experience and expertise in the design, implementation and realization of clinical trials, particularly in the fields of HIV, malaria, tuberculosis, hepatitis C, and other infectious diseases. The VIC has been designed to conduct mainly phase I and II trials, with the main goals being the assessment of safety, as well as the evaluation of the immune responses to experimental vaccines.

The Vaccine and Immunotherapy Center (VIC) Community Advisory Board (CAB)

In addition, the VIC formed a Community Advisory Board (CAB) in June 2007. The CAB was created with 7 founding members from various backgrounds and now has 10 members. The CAB acts as a spokesperson for civil society, in order to open a dialogue with the scientific researchers working in the field of HIV/AIDS. Its goal is to identify the questions or misunderstandings that the population may have, in order to continuously improve the quality of information given by the researchers.


For more information, please visit the VIC website.